Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease

Trial Profile

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms DIVERSITY
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 22 Nov 2016 According to a Galapagos NV media release, the first patient in this trial has been dosed.
    • 15 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 27 Sep 2016 According to Galapagos NV media release, the company reports the successful completion of discussions with the regulatory authorities in the US and Europe to initiate the DIVERSITY Phase 3 study in Crohn's disease and first dosing is expected in Q4'16.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top